BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 22543588)

  • 21. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
    Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
    J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY; Zhao MB; Zhuang GB; Li PP
    Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.
    Kim YH; Sumiyoshi S; Hashimoto S; Masago K; Togashi Y; Sakamori Y; Okuda C; Mio T; Mishima M
    Clin Lung Cancer; 2012 Sep; 13(5):385-90. PubMed ID: 22285568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
    Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
    J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
    Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
    Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells.
    Mohammed Ael S; Eguchi H; Wada S; Koyama N; Shimizu M; Otani K; Ohtaki M; Tanimoto K; Hiyama K; Gaber MS; Nishiyama M
    Exp Lung Res; 2012 Nov; 38(9-10):463-74. PubMed ID: 23098063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell.
    Li N; Li X; Li S; Zhou S; Zhou Q
    Biochem Biophys Res Commun; 2013 Sep; 439(2):187-90. PubMed ID: 23994634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
    Sordella R; Bell DW; Haber DA; Settleman J
    Science; 2004 Aug; 305(5687):1163-7. PubMed ID: 15284455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
    Wong JC; Bathina M; Fiscus RR
    J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.
    Ando K; Ohmori T; Inoue F; Kadofuku T; Hosaka T; Ishida H; Shirai T; Okuda K; Hirose T; Horichi N; Nishio K; Saijo N; Adachi M; Kuroki T
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8872-9. PubMed ID: 16361577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer.
    Wang HH; Wang YC; Wu DW; Hung CS; Chen CY; Lee H
    Tumour Biol; 2017 Apr; 39(4):1010428317694316. PubMed ID: 28378642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphorylation of IGFBP-3 by Casein Kinase 2 Blocks Its Interaction with Hyaluronan, Enabling HA-CD44 Signaling Leading to Increased NSCLC Cell Survival and Cisplatin Resistance.
    Coleman KL; Chiaramonti M; Haddad B; Ranzenberger R; Henning H; Al Khashali H; Ray R; Darweesh B; Guthrie J; Heyl D; Evans HG
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells.
    Lin Y; Wang Z; Liu L; Chen L
    Lung Cancer; 2011 Mar; 71(3):291-7. PubMed ID: 20599289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors.
    Juliachs M; Muñoz C; Moutinho CA; Vidal A; Condom E; Esteller M; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
    Clin Cancer Res; 2014 Feb; 20(3):658-67. PubMed ID: 24277456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
    Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
    Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
    Galluzzi L; Morselli E; Vitale I; Kepp O; Senovilla L; Criollo A; Servant N; Paccard C; Hupé P; Robert T; Ripoche H; Lazar V; Harel-Bellan A; Dessen P; Barillot E; Kroemer G
    Cancer Res; 2010 Mar; 70(5):1793-803. PubMed ID: 20145152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
    Haura EB; Zheng Z; Song L; Cantor A; Bepler G
    Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
    Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
    Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3.
    Jin Q; Lee HJ; Min HY; Smith JK; Hwang SJ; Whang YM; Kim WY; Kim YH; Lee HY
    Carcinogenesis; 2014 Oct; 35(10):2232-43. PubMed ID: 24942865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.